Overview

A Study of LAD191 in Adults With Hidradenitis Suppurativa

Status:
NOT_YET_RECRUITING
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess the efficacy of multiple dosing regimens of LAD191 compared to placebo in participants with moderate-to-severe Hidradenitis Suppurativa (HS) and to access the safety, tolerability, pharmacokinetic and immunogenicity in participants with moderate-to-severe HS.
Phase:
PHASE2
Details
Lead Sponsor:
Almirall, S.A.
Treatments:
Adalimumab